The final word in target validation is to reintroduce an RNAi-resistant version of the target gene product into depleted cells and show recovery of function. This can be challenging for large sets ...

Scientists seek innovative approaches to address this health crisis, some of which are therapeutics poised to treat CVD in new ways. RNA interference (RNAi) therapeutics silence genes, disrupting the ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced presentation of preclinical data supporting the advancement of ...

The most recent addition to the methods hall of fame is RNA interference (RNAi). The discovery of a whole universe of small RNAs with regulatory functions of fundamental importance was entirely ...

In 2002, on the heels of the discovery that RNA interference existed in human cells, the usually reserved journal Science proclaimed RNAi the "breakthrough of the year." Here was a part of the ...

While there are RNAi products on the marketplace, with Alnylam becoming the first company to get a product approved in 2018, it is difficult to get this class of drug distributed through the brain ...

Net product revenues increased 30.2% to $450.8 ... Alnylam Pharmaceuticals is a leader in RNA interference (RNAi), a cutting-edge technology that targets RNA to silence genes involved in diseases.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Stifel 2025 Virtual CNS Forum on Tuesday, ...

BOSTON--(BUSINESS WIRE)--Atalanta Therapeutics, a biotechnology company pioneering RNA interference (RNAi) for the treatment of neurological diseases, today announced the completion of a $97 ...

Silexion recently announced the completion of its initial study evaluating SIL-204 in orthotopic pancreatic cancer models, a critical milestone that could continue to position its next-generation RNAi ...